ReviewJournal of clinical medicine2025
The Rise of Total-Body PET/CT: Advancing Molecular Imaging Toward Early Cancer Detection and Potential Future Application in Prevention Healthcare.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating Multiparametric MRI and PSMA PET Imaging in Prostate Cancer: Toward a Unified Diagnostic and Risk-Stratification Paradigm.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Positron Emission Tomography (PET) is undergoing a profound transformation. Driven by the convergence of highly sensitive long-axial field-of-view (LAFOV) total-body PET systems and an expanding portfolio of targeted radiopharmaceuticals, PET is progressively evolving beyond its traditional role in oncologic diagnosis and staging. Ultra-sensitive scanners enable whole-body imaging with markedly reduced radiotracer doses, rapid acquisition times, and true dynamic multiparametric imaging across all organs simultaneously. In parallel, molecularly targeted radioligands support tumour phenotyping, theranostic applications, and personalized dosimetry. Together, these advances position PET as a systemic imaging platform capable of interrogating whole-body tumour biology, guiding precision therapies, and potentially enabling early detection or surveillance strategies in selected high-risk populations. This narrative review summarizes the technological foundations of total-body PET, reviews current clinical and translational applications, discusses opportunities and limitations for early detection and surveillance, and outlines a research and implementation roadmap to responsibly translate this paradigm into clinical oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.